ENGN enGene Holdings Inc.

Nasdaq


$ 6.50 $ -0.35 (-5.11 %)    

Thursday, 20-Nov-2025 13:58:09 EST
QQQ $ 589.88 $ -21.79 (-3.56 %)
DIA $ 458.60 $ -8.08 (-1.73 %)
SPY $ 655.65 $ -17.25 (-2.56 %)
TLT $ 89.25 $ 0.26 (0.3 %)
GLD $ 373.49 $ -1.69 (-0.45 %)
$ 6.76
$ 7.01
$ 6.46 x 100
$ 6.59 x 11
$ 6.50 - $ 7.06
$ 2.65 - $ 11.14
1,749,729
na
345.47M
$ 0.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-11-2025 07-31-2025 10-Q
2 06-12-2025 04-30-2025 10-Q
3 03-10-2025 01-31-2025 10-Q
4 12-19-2024 10-31-2024 10-K
5 09-10-2024 07-31-2024 10-Q
6 06-14-2024 04-30-2024 10-Q
7 03-11-2024 01-31-2024 10-Q
8 01-29-2024 10-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and raises the price target fr...

Core News & Articles

Oppenheimer analyst Leland Gershell reiterates enGene Holdings (NASDAQ:ENGN) with a Outperform and raises the price target f...

Core News & Articles

UBS analyst Colin Bristow maintains enGene Holdings (NASDAQ:ENGN) with a Neutral and raises the price target from $4 to $10.

Core News & Articles

Citizens analyst Silvan Tuerkcan maintains enGene Holdings (NASDAQ:ENGN) with a Market Outperform and raises the price targe...

 engene-encouraged-by-promising-response-rates-in-bladder-cancer-trial

enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.

Core News & Articles

enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and lowers the price target fr...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with a Buy and maintains $25 pr...

Core News & Articles

enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with a Buy and maintains $25 pr...

Core News & Articles

Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achievedenGene plans to provide an update fro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION